Literature DB >> 31383994

A reality check of the accelerated approval of immune-checkpoint inhibitors.

Jennifer Gill1,2, Vinay Prasad3,4,5,6.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31383994     DOI： 10.1038/s41571-019-0260-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.

Authors:  Désirée Tampe; Sarah Birgit Kopp; Eva Baier; Samy Hakroush; Björn Tampe
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.

Authors:  Pedro Rocha; Jiexin Zhang; Raquel Laza-Briviesca; Alberto Cruz-Bermúdez; Neus Bota-Rabassedas; Beatriz Sanchez-Espiridon; Katsuhiro Yoshimura; Carmen Behrens; Wei Lu; Ximing Tang; Apar Pataer; Edwin R Parra; Cara Haymaker; Junya Fujimoto; Stephen G Swisher; John V Heymach; Don L Gibbons; J Jack Lee; Boris Sepesi; Tina Cascone; Luisa M Solis; Mariano Provencio; Ignacio I Wistuba; Humam Kadara
Journal:  Clin Cancer Res       Date:  2022-06-01       Impact factor: 13.801

Review 3.  Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.

Authors:  Dmitrii Shek; Scott A Read; Adnan Nagrial; Matteo S Carlino; Bo Gao; Jacob George; Golo Ahlenstiel
Journal:  Oncologist       Date:  2021-04-21

Review 4.  The Future of Clinical Trial Design in Oncology.

Authors:  Anna Spreafico; Aaron R Hansen; Albiruni R Abdul Razak; Philippe L Bedard; Lillian L Siu
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 38.272

Review 5.  Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.

Authors:  Niloy R Datta; H Petra Kok; Hans Crezee; Udo S Gaipl; Stephan Bodis
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

6.  Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.

Authors:  Samy Hakroush; Sarah Birgit Kopp; Désirée Tampe; Ann-Kathrin Gersmann; Peter Korsten; Michael Zeisberg; Björn Tampe
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

7.  Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.

Authors:  Valerio Gristina; Antonio Galvano; Luisa Castellana; Lavinia Insalaco; Stefania Cusenza; Giuseppa Graceffa; Federica Iacono; Nadia Barraco; Marta Castiglia; Alessandro Perez; Sergio Rizzo; Antonio Russo; Viviana Bazan
Journal:  Ther Adv Med Oncol       Date:  2021-07-21       Impact factor: 8.168

8.  The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

Authors:  Timothée Olivier; Vinay Prasad
Journal:  Transl Oncol       Date:  2022-02-20       Impact factor: 4.243

9.  Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.

Authors:  Peey-Sei Kok; Won-Hee Yoon; Sally Lord; Ian Marschner; Michael Friedlander; Chee Khoon Lee
Journal:  JCO Precis Oncol       Date:  2021-07-15

10.  Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

Authors:  David Bomze; Nethanel Asher; Omar Hasan Ali; Lukas Flatz; Daniel Azoulay; Gal Markel; Tomer Meirson
Journal:  JAMA Netw Open       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.